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The goals of the Association for Molecular Pathology Clinical Practice Committee’s Pharmacogenomics
(PGx) Working Group are to deﬁne the key attributes of pharmacogenetic alleles recommended for
clinical testing, and to determine a minimal set of variants that should be included in clinical PGx
genotyping assays. This document series provides recommendations on a minimal panel of variant
alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories in
designing assays for PGx testing. When developing these recommendations, the Association for Molecular Pathology PGx Working Group considered the functional impact of the variant alleles, allele
frequencies in multiethnic populations, the availability of reference materials, as well as other technical
considerations with regard to PGx testing. The ultimate goal of this Working Group is to promote
standardization of PGx gene/allele testing across clinical laboratories. This document is focused on

Standard of practice is not deﬁned by this article and there may be alternatives. See Disclaimer for further details.
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clinical CYP2D6 PGx testing that may be applied to all cytochrome P450 2D6emetabolized medications.
These recommendations are not meant to be interpreted as prescriptive but to provide a reference guide
for clinical laboratories that may be either implementing PGx testing or reviewing and updating their
existing platform. (J Mol Diagn 2021, 23: 1047e1064; https://doi.org/10.1016/j.jmoldx.2021.05.013)

To address variability in clinical pharmacogenomics (PGx)
testing, and to facilitate standardization across laboratories,
the Association for Molecular Pathology (AMP) PGx
Working Group has developed a series of documents that
recommend a minimal set of variant alleles for inclusion in
clinical PGx assays. Previous documents have covered
CYP2C19,1 CYP2C9,2 and genes important for warfarin
PGx testing.3 The current document is focused on CYP2D6
and is intended to provide guidance for clinical laboratorians and assay manufacturers who develop, validate,
and/or offer clinical CYP2D6 genotyping assays, and
therefore to promote the standardization of PGx testing
across clinical laboratories. This document should be
implemented together with other relevant clinical guidelines, including those published by the Clinical Pharmacogenetics Implementation Consortium (CPIC),4e9 Dutch
Pharmacogenetics Working Group of the Royal Dutch
Pharmacists Association (DPWG) Canadian PGx Network
for Drug Safety,10 and the American College of Medical
Genetics and Genomics,11 which have mostly been focused
on the interpretation of PGx test results and therapeutic
recommendations on speciﬁc drug-gene pairs.
The AMP PGx Working Group uses a two-tier strategy
and selection criteria for recommending PGx variants for
clinical testing.1e3 Tier 1 PGx variant alleles are a minimal
set recommended for clinical testing, while Tier 2 variant
alleles do not meet all criteria for inclusion in Tier 1 but may
be considered for clinical testing. As deﬁned in previous
guidelines,1e3 Tier 1erecommended variant alleles meet the
following criteria: i) have a well-characterized effect on the
function of the protein and/or gene expression, ii) have an
appreciable minor allele frequency in a population/ethnicity
group, and iii) have publicly available reference materials

(RMs). Tier 2erecommended variant alleles meet at least
one but not all of the Tier 1 criteria, and may be moved to
Tier 1 if RMs or additional information becomes available.
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CYP2D6
The cytochrome P450 (CYP) 2D6 enzyme, encoded by
CYP2D6, is a member of the 2D subfamily of CYP enzymes
and is involved in the metabolism of many commonly
prescribed medications, including some antidepressants,
atypical and typical antipsychotics, b-blockers, opioids,
antiemetics, atomoxetine, and tamoxifen.12,13 About 21% of
currently approved medications are metabolized by
CYP2D6.14 Interindividual variation in CYP2D6 activity
varies substantially and can be attributed, at least in part, to
numerous genetic variants in CYP2D6 in the general population. These variants cause increased-function, decreasedfunction, or nonfunctional CYP2D6 enzyme.
Clinical CYP2D6 testing involves the determination of
sequence and structural variants by targeted genotyping or
sequencing, followed by empirical assignment of detected
variants into star (*) alleles or haplotypes. A haplotype is a
combination of sequence variants from multiple loci on a
single chromosome, and a diplotype is composed of two
haplotypes from the maternal and paternal chromosomes.
Although the terms genotype and diplotype are often used
interchangeably in PGx literature, in this document, genotype
refers to sequence variants identiﬁed by molecular platforms
that will then be assembled to haplotypes (alleles) and diplotypes. Both genotype and copy number results are combined to assemble haplotypes and diplotypes. CYP2D6
diplotypes are typically stratiﬁed into four groups that
represent a patient’s predicted CYP2D6 metabolizer
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phenotype: ultrarapid metabolizer, normal metabolizer (NM),
intermediate metabolizer, and poor metabolizer.15 Importantly, CYP2D6 metabolizer phenotype has signiﬁcant consequences on drug safety and effectiveness, prompting the
CYP2D6 gene to be broadly included in the US Food and
Drug Administration’s (FDA) Table of Pharmacogenetic
Associations (https://www.fda.gov/medical-devices/precisionmedicine/table-pharmacogenetic-associations, last accessed
September 27, 2020), and Table of Pharmacogenomic
Biomarkers in Drug Labeling (https://www.fda.gov/drugs/
science-and-research-drugs/table-pharmacogenomic-bio
markers-drug-labeling, last accessed September 27, 2020).
CYP2D6 has nine exons and is located on chromosome
22q13.2 next to two highly homologous pseudogenes,
CYP2D7 and CYP2D8.16 It is highly polymorphic, with
over 130 star allele haplotypes deﬁned by the Pharmacogene
Variation Consortium (PharmVar, www.pharmvar.org, last
accessed September 23, 2020).17 Most of the CYP2D6 star
alleles are deﬁned by single-nucleotide variants or small
insertion/deletions. CYP2D6 can also harbor copy-number
variants (CNVs; deletions and duplications) and gene conversions with the nearby CYP2D7 pseudogene, leading to
CYP2D6-2D7 and CYP2D7-2D6 hybrid alleles.16,18e20
Clinical laboratories offering CYP2D6 PGx testing
mostly use a targeted genotyping approach. However, the
large numbers of CYP2D6 alleles and structural variants
make analysis of this gene challenging.16,19,20 A Genetic
Testing Reference Material Program study21 found little
consistency in alleles included in CYP2D6 clinical tests
across multiple laboratories. In addition, many assays were
not designed for the detection of CNVs or other structural
variants. A study in over 100,000 patient samples across all
regions of the United States showed that structural variants,
including CNVs, accounted for 7% of all CYP2D6 variants
and could affect CYP2D6 metabolizer status.22 Therefore,
the variability in assay design, with or without the detection
of CNVs and structural variants, can result in discrepancies
in star allele calls and diplotype assignment, which directly
affect phenotype translation, interpretation, and ultimately a
patient’s care.23,24

Clinical Testing
According to the National Institutes of Health Genetic Testing
Registry
(https://www.ncbi.nlm.nih.gov/gtr/all/tests/?
termZ1565%5bgeneid%5d, last accessed October 29,
2020), CYP2D6 variants tested in US clinical laboratories
range from a few targeted haplotype-deﬁning variants to the
analysis of selected exons or the entire coding region of the
gene. Testing methods include targeted genotyping employing
various laboratory-developed procedures or commercial platforms, single-nucleotide polymorphismebased microarrays,
and full-gene Sanger or next-generation sequencing approaches, with or without deletion/duplication and structure
variant analysis. For gene duplications, some laboratories offer
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additional testing, for example using long-range PCR12,25e27
to determine which allele is duplicated in order to provide a
more accurate activity score assignment and phenotype prediction.15,28 Regardless of whether a targeted genotyping or a
full-gene sequencing approach is used, most laboratories
speciﬁcally test for haplotype-deﬁning variants and empirically assign diplotypes. Next-generation, short-read
sequencing presents many challenges, including the accurate
distinction of CYP2D6 sequence variants versus interfering
pseudogenes, the characterization of structural variants,
phasing of variants for the assignment of haplotype and diplotype, and the interpretation of novel or rare haplotypes.
Recent studies have addressed some of these technical challenges by using full-gene, single-molecule, real-time
sequencing with the Paciﬁc Biosciences platform21,29 and
allele-speciﬁc ampliﬁcation combined with long-range PCR
sequencing for the comprehensive characterization of fulllength CYP2D6 haplotypes.21,29 In addition, bioinformatics
tools have been developed to computationally infer CYP2D6
star
allele
diplotypes
from
next-generation
sequencingederived variant call format and binary alignment map ﬁles.30e36

Existing Guidelines
Clinical PGx guidelines are available from professional
societies, including the CPIC, Dutch Pharmacogenetics
Working Group of the Royal Dutch Pharmacists Association (DPWG), Canadian PGx Network for Drug Safety, and
American College of Medical Genetics and Genomics. At
the time of the publication of the present article, CPIC has
published six CYP2D6-related guidelines with dosing recommendations on 14 medications.4e9 Although some clinical PGx guidelines have included summaries of known
CYP2D6 alleles, frequencies in various populations, and
their functional and/or clinical relevance, they do not
explicitly recommend speciﬁc variant alleles for inclusion in
CYP2D6 genotyping in clinical laboratories. Speciﬁc considerations for diagnostic laboratories, such as allele selection, testing platforms, and the availability of RMs, have not
been the focus of the other clinical practice guidelines.
However, consistency of genotyping tests among clinical
laboratories will facilitate the use of these important clinical
PGx practice guidelines and the clinical implementation of
PGx testing in general.

Materials and Methods
The AMP PGx Working Group comprises PGx experts from
the CPIC, College of American Pathologists (CAP), DPWG
and the PGx clinical testing and research communities.
CYP2D6 alleles, including the *5 gene deletion, alleles with
gene duplications, and alleles having one or more gene
copies consisting of a combination of portions of CYP2D6
and CYP2D7 (commonly referred to as hybrid genes or
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Table 1

Reference Materials

Allele

Coriell cell line no.

Diplotype

Coriell cell line no.

Diplotype

*2
*3
*4
*5
*6
*7
*9
*10
*11
*13
*14
*15
*17
*21
*22
*28
*29
*31
*33
*35
*36
*39
*40
*41
*43
*45
*46
*52
*56
*58
*59
*68
*71
*82
*83
*90
*99
*106
*108
*111
*112
*113
Other structural variants (gene deletion,
duplication, hybrids, and tandem arrangements)

HG00373
*2/*2
NA19226
*2/*22
HG00111
*3/*3
NA17176
*3/*45
NA15245
*42/*4
NA19174
*4/*40
NA19317
*5/*5
HG03246
*5/*43
NA24027
*22/*6
NA20289
*6/*11
HG03643
*2/*7
NA06989
*9/*9
NA19143
*2(*45)/*10
NA19207
*22/*10
NA20289
*6/*11
NA19790
*1/*13þ*2
NA19785
*1/*13þ*2
NA18552
*1/*14
HG02373
*14/*36þ*10
NA19239
*15/*17
NA23877
*15/*41
NA23297
*102/*17
NA17169
*17/*56
NA18973
*1/*21
HG00589
*1/*21
HG00337
*22/*22
NA20803
*2/*22
HG01680
*28/*59
NA17448
*1/*28
NA17137
*29/*45
NA19109
*22/*29
HG01086
*1/*31
HG01094
*1/*31
NA12154
(*68)þ*4/*33
NA07029
*1/*35
NA12003
*4/*35
NA18563
*1/*36þ*10
NA18565
*10/*362
NA23878
(*4N)þ*4/*39
NA19917
*1/*40
NA19174
*4/*40
NA18544
*10/*41
NA18540
(*36þ)10/*41
HG03246
*5/*43
NA17128
*1/*43
NA17137
*29/*45
NA17176
*3/*45
NA19908
*1/*46
NA18632
*362þ*10/*52
NA17169
*17/*56
HG03225
*5/*56
NA17185
*4/*58
NA19180
*1/*58
HG01680
*28/*59
HG01190
*68þ*4/*5
NA21781
*22/*68þ*4
HG00436
*22/*71
NA19777
*1/*82
NA17287
*1/*83
NA18642
*36þ*10/*1þ*90
HG03703
*1/*99
HG03781
*2/*99
HG03259
*5/*106
HG01108
*2/*106
NA17222
*2/*108
NA20875
*1/*111
NA21105
*3/*111
HG03780
*1/*112
HG03882
*1/*112
HG04206
*2/*113
HG03619
*2/*113
*12, *22, *42, *4Nþ*4, *5, *102, *13þ*2, *172, *362, *36þ*1,
*36þ*10, *362þ*10, *362þ*102, *413, and *68þ*4

Additional reference materials for many of these alleles are also available22,37,38 (Centers for Disease Control and Prevention, https://www.cdc.gov/
labquality/get-rm/inherited-genetic-diseases-pharmacogenetics/pharmacogenetics.html, last accessed July 27, 2021). Genotypes in parentheses were
determined in only one laboratory and not conﬁrmed.

hybrid alleles), were reviewed and stratiﬁed into tiers on the
basis of four criteria: i) functional characterization status of
the allele, that is, whether it is known to affect the function of
the gene or encoded protein; ii) presence at an appreciable
minor allele frequency (MAF) in a population/ethnicity [in
this particular document on CYP2D6, the Working Group
used a MAF of 1% for Tier 1 alleles, and 0.1% for Tier 2
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alleles, based on currently available information from applicable resources (PharmGKB, https://www.pharmgkb.org/
gene/pa128, last accessed October 29, 2020)]; iii) the
availability of RMs (Table 1)22,37,38; and iv) the technical
feasibility of clinical laboratories to detect the variant.
These criteria received equal weight in the deliberations
of the AMP PGx Working Group. Of note, the fourth
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criterion regarding technical feasibility was added to this
document due to the complexity of CYP2D6 testing of some
of the variants (Results). This additional criterion was not
included in previous recommendations published by this
Working Group because the variants in the genes described
in those recommendations were detectable using standard
clinical laboratory methods.1e3 Additionally, commercially
available genotyping platforms (Supplemental Table S1)
were reviewed for an understanding of the capacity of laboratories to implement the Working Group’s recommendations; however, these data were not used as part of the
determination of Tier assignment.
The AMP PGx Working Group utilized information on
MAF and function from CPIC, PharmGKB, and the scientiﬁc
literature. Because part of the process that the CPIC uses for
developing clinical dosing guidelines includes curating allele
frequencies and function assignments,39,40 the PGx Working
Group used the CPIC’s curated information. In the case of
CYP2D6, in which some star alleles are a combination of
multiple variants and certain variants may be present in
multiple alleles in different combinations with other variants,
sequence variant frequencies from databases such as the
Genome Aggregation Database (gnomAD, https://gnomad.
broadinstitute.org, last accessed September 17, 2020) and
the International Genome Sample Resource (commonly
referred to as 1000 Genomes, https://www.international
genome.org, last accessed September 17, 2020) may not
accurately represent CYP2D6 star allele frequencies. CPIC
relied on studies that speciﬁcally examined star allele
haplotype frequencies. Dependence on the literature results
in several caveats with regard to the calculated allele
frequencies, including that: i) most studies test for a limited
number of alleles, and some alleles are rarely assayed or
reported in the literature; ii) some studies do not test for
CNVs and structural variants, which can result in
inaccurate allele assignment; and iii) some studies test for a
limited number of sequence variants and default allele
assignment (eg, assigning all alleles with the c.100C>T
variant as CYP2D6*10). As a result, allele frequencies can
be under- or overestimated or simply not detected. The
assignment of the clinical function of alleles by CPIC is
based on ﬁndings from literature reviews of allele function.
Of note, CPIC-deﬁned clinical function may not be the
same as the biochemical function of the allele. Although
PharmVar (https://www.pharmvar.org/gene/cyp2d6, last
accessed October 6, 2020) listed over 130 CYP2D6 alleles,
the CPIC had evaluated alleles up to *114 as of mid-2020.
Therefore, the present recommendation document from the
AMP PGx Working Group considers CYP2D6 alleles
through only *114.
The percentage of laboratories that included speciﬁc
variants in clinical CYP2D6 testing was calculated based on
data obtained from CAP Proﬁciency Testing data. Laboratories self-report whether their test is designed to detect each
of the indicated alleles. Survey data were obtained from the
2019-A and -B mailings. While many subscribers to the
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CAP PGx proﬁciency testing program are US-based, there
are also international participants. Additionally, data were
obtained from the German-based Reference Institute for
Bioanalytics Molecular Genetics Group 2, which has a
panel that includes CYP2D6.

Results
Tier 1 CYP2D6 Variant Alleles
CYP2D6 variant star alleles recommended for inclusion in
Tier 1 include CYP2D6 *2 to *6, *9, *10, *17, *29, and
*41, and the presence or absence of a gene duplication or
multiplication (Table 2).
CYP2D6*2
CYP2D6*2 is a commonly reported allele with normal function and is characterized by two common missense variants,
one in exon 6 [NM_000106.6:c.886C>T (dbSNP, https://
www.ncbi.nlm.nih.gov/snp, last accessed May 10, 2021; p.
Arg296Cys, rs16947, legacy 2850C>T) and one in exon 9
(NM_000106.6:c.1457G>C,
p.Ser486Thr,
rs1135840,
legacy 4180G>C). The CYP2D6*2 allele frequency varies
among different populations with approximately 28% in
Europeans, 16% to 20% in those of African ancestry, and
12% to 29% in Asian populations (Central/South and East
Asian; PharmGKB, https://www.pharmgkb.org/gene/pa128).
This allele would not typically meet the Working Group
criteria for Tier 1 variants, as it does not result in altered
CYP2D6 function unless it is duplicated or multiplicated,
which does meet criteria; however, the Working Group
decided to include CYP2D6*2 in Tier 1 because c.886C>T
and/or c.1457G>C is often tested for in laboratories to
disambiguate CYP2D6*2 and other CYP2D6 alleles that
include these variants (Tables 2 and 3).
CYP2D6*3
The no-function CYP2D6*3 allele is characterized by a
single-nucleotide
deletion
(NM_000106.6:c.775del,
p.Arg259fs, rs35742686, legacy 2549delA) in exon 5 that
causes a frameshift and premature truncation of the
CYP2D6 protein, and subsequently a loss of enzyme
function.41e43 CYP2D6*3 occurs at a frequency of
approximately 1.6% in populations of European ancestry,
but <1% in other ancestral populations (PharmGKB,
https://www.pharmgkb.org/gene/pa128,
last
accessed
October 29, 2020).
CYP2D6*4
The CYP2D6*4 allele is a no-function allele characterized
by a splicing defect variant (NM_000106.6:c.506-1G>A,
rs3892097, legacy 1846G>A) located in the splice junction
between intron 3 and exon 4 that results in a nonfunctional
protein.44,45 CYP2D6*4 is the allele that contributes most
commonly to the CYP2D6 poor metabolizer phenotype.
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Table 2

CYP2D6 Tier 1 Variant Alleles

Allele functional status
Allele assigned by CPICy

Core variant(s)z

Legacy nomenclature
(M33388) ATG startx,{

RefSeqGene LRG_303
(NG_008376.4)
ATG startx

*2

Normal function

rs16947, rs1135840

2850C>T, 4180G>C

2851C>T, 4181G>C

*3
*4
*5
*6
*9
*10

No function
No function
No function
No function
Decreased function
Decreased function

rs35742686
rs3892097
CYP2D6 full gene deletion
rs5030655
rs5030656
rs1065852, rs1135840

2549delA
1846G>A

2550delA
1847G>A

1707delT
2615delAAG
100C>T, 4180G>C

1708delT
2616delAAG
100C>T, 4181G>C

*17

Decreased function

rs28371706, rs16947, rs1135840

1023C>T, 2850C>T, 4180G>C

1022C>T, 2851C>T, 4181G>C

*29

Decreased function

rs59421388, rs61736512þ
rs1058164, rs16947, rs1135840

3183G>A, 1659G>A, 1661G>C,
2850C>T, 4180G>C

3184G>A, 1660G>A, 1662G>C,
2851C>T, 4181G>C

*41

Decreased function

rs28371725, rs16947, rs1135840

2988G>A, 2850C>T, 4180G>C

2989G>A, 2851C>T, 4181G>C

N

Variable, depending the Duplications
duplicated alleles

(table continues)
y

Citations for assignment of function can be found on the Pharmacogene Variation Consortium website (https://www.pharmvar.org, last
accessed October 28, 2020); HGVS nomenclature can be found on the National Center for Biotechnology Information website (https://www.
ncbi.nlm.nih.gov/snp and http://www.ncbi.nlm.nih.gov/clinvar, both last accessed October 28, 2020).
z
Core variant(s) can be found on the Pharmacogene Variation Consortium website (https://www.pharmvar.org, last accessed October 28,
2020); the characteristic variant associated with altered function and corresponding HGVS nomenclature for each star allele are underlined.
x
Count from ATG start site.
{
The reference sequence initially used for deﬁning variants, M33388, differs from the current RefSeq NG_008376.4 at four positions, of
which three are insertion/deletions and thus causes variant coordinates to shift among these reference sequences (https://www.pharmvar.
org/gene/cyp2d6, last accessed October 6, 2020). Positions on M33388 are referred to as “legacy.”
CPIC, Clinical Pharmacogenetics Implementation Consortium; HGVS, Human Genome Variation Society.

This allele is found in European populations at a frequency
of approximately 18.5%, whereas its frequency ranges between 3% and 5% in those of African ancestry and from
0.5% to 9.1% in Asian (Central/South and East Asian)
populations (PharmGKB, https://www.pharmgkb.org/gene/
pa128). The c.100C>T variant (p.Pro34Ser, rs1065852,
legacy 100C>T) is also present in all but one CYP2D6*4
haplotype (ie, the *4.012 suballele). Additionally, c.
100C>T, which causes decreased function, is present in
the CYP2D6 *10 and *36 alleles and in several other
CYP2D6 alleles/haplotypes.
CYP2D6*5
The no-function CYP2D6*5 allele is characterized by a full
gene deletion, resulting in the absence of CYP2D6 protein
and loss of enzyme function.46 The allele frequencies of
CYP2D6*5 are approximately 3% to 5% in African, Asian
(Central/South and East Asian), and European populations
(PharmGKB, https://www.pharmgkb.org/gene/pa128).
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CYP2D6*6
The no-function CYP2D6*6 allele is characterized by a singlenucleotide deletion in exon 3 (NM_000106.6:c.454del,
p.Trp152fs, rs5030655, legacy 1707delT), causing a frameshift and premature truncation of the CYP2D6 protein,
resulting, in turn, in the loss of enzyme function.47 The frequencies of CYP2D6*6 are approximately 1% in European
populations and 0.5% or lower in other populations
(PharmGKB, https://www.pharmgkb.org/gene/pa128).
CYP2D6*9
The CYP2D6*9 allele is a decreased-function allele characterized by the deletion of three nucleotides that results in the
loss of a lysine at amino acid position 281 in exon 5
(NM_000106.6: c.841_843del, p.Lys281del, rs5030656, legacy 2615delAAG) and decreased enzyme function.48,49 The
CYP2D6*9 frequencies are approximately 2.8% and 1.6% in
European and Latino populations, respectively, and <0.5% in
African ancestry and Asian (Central/South and East Asian)
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Table 2 (continued)
RefSeqGene
LRG_303
(NG_008376.4)

HGVS genomic
nomenclature: GRCh38
(NC_000022.11)

HGVS cDNA
nomenclature: LRG_303
(NM_000106.6x)

HGVS protein nomenclature:
LRG_303 (NP_000097.3)

Reference
material Multiethnic allele
available frequency

g.7870C>T,
g.9200G>C
g.7569del
g.6866G>A

g.42127941G>A,
g.42126611C>G
g.42128242del
g.42128945C>T

c.886C>T, c.1457G>C

p.Arg296Cys, p.Ser486Thr

Yes

3.9%e29.5%

c.775del
c.506-1G>A

p.Arg259fs
(splicing defect)

g.6727del
g.7635_7637del

g.42129084del
g.42128176_
42128178del
g.42130692G>A,
g.42126611C>G
g.42129770G>A,
g.42127941G>A,
g.42126611C>G
g.42127608C>T,
g.42525132_
42525134delinsGAT,
g.42127941G>A,
g.42126611C>G
g.42127803C>T,
g.42127941G>A,
g.42126611C>G

c.454del
c.841_843del

p.Trp152fs
p.Lys281del

Yes
Yes
Yes
Yes
Yes

<0.1%e1.6%
0.5%e18.5%
1.6%e5.4%
0%e1.1%
0%e2.8%

c.100C>T, c.1457G>C

p.Pro34Ser, p.Ser486Thr

Yes

1.4%e43.6%

c.320C>T, c.886C>T,
c.1457G>C

p.Thr107Ile, p.Arg296Cys,
p.Ser486Thr

Yes

<0.1%e19.3%

c.1012G>A,
c.406_408delinsATC,
c.886C>T, c.1457G>C

p.Val338Met, p.Val136Ile,
p.Arg296Cys, p.Ser486Thr

Yes

0%e12.1%

c.985þ39G>A, c.886C>T,
c.1457G>C

N/A (splicing defect), p.Arg296Cys,
p.Ser486Thr

Yes

0.8%e15.4%

g.5119C>T,
g.9200G>C
g.6041C>T,
g.7870C>T,
g.9200G>C
g.8203G>A,
g.6679G>A
g.6681G>C,
g.7870C>T,
g.9200G>C
g.8008G>A,
g.7870C>T,
g.9200G>C

Yes

populations (PharmGKB, https://www.pharmgkb.org/gene/
pa128). The c.841_843del variant is also found in
combination with other sequence variants on two other rare
and not well-characterized alleles, *109 and *115.
CYP2D6*10
The decreased-function CYP2D6*10 allele is characterized
by a missense variant in exon 1 (NM_000106.6: c.100C>T,
p.Pro34Ser, rs1065852, legacy 100C>T).50e52 This allele
also contains the common c.1457G>C variant. CYP2D6*10
is most common in the Asian population (South/Central and
East Asian), with an allele frequency ranging from 9% to
44%, whereas the frequencies are 4% to 6% in those of
African ancestry and <2% in the European population
(PharmGKB,
https://www.pharmgkb.org/gene/pa128).
Accurately assigning CYP2D6*10 is challenging given
that c.100C>T is also present in many other CYP2D6
allele haplotypes, including *4, *36, *37, *47, *49, *52,
*54, *56, *57, *64, *65, *69, *72, *87, *94, *95, *99,
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Variable

*100, *101, *114, and *132 (PharmVar, https://www.
pharmvar.org/gene/cyp2d6).
CYP2D6*17
The decreased-function CYP2D6*17 allele is characterized
by a missense variant in exon 2 (NM_000106.6:c.320C>T,
p.Thr107Ile, rs28371706, legacy 1023C>T), and includes
the two common variants c.886C>T and c.1457G>C.
CYP2D6*17 is most common in those of African ancestry,
with an allele frequency of 17% to 19%, but is <0.5% in
European and Asian (Central/South and East Asian) populations. Additionally, this allele occurs in approximately
2.3% in the Latino population (PharmGKB, https://www.
pharmgkb.org/gene/pa128). The variant c.320C>T is also
present in the *40 allele (in Tier 2), as well as in *58 and *64.
CYP2D6*29
The decreased-function CYP2D6*29 allele is characterized by
two
missense
variants,
NM_000106.6:c.1012G>A
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Table 3

CYP2D6 Tier 2 Variant Alleles

Allele

Allele functional
status assigned
by CPICy
Core variant(s)z

*7
*8

No function
No function

*12

No function

*14

Legacy nomenclature
(M33388) ATG startx,{

RefSeqGene LRG_303
RefSeqGene LRG_303
(NG_008376.4) ATG startx (NG_008376.4)

rs5030867
rs5030865, rs16947,
rs1135840
rs5030862, rs16947,
rs1135840

2935A>C
2936A>C
1758G>T, 2850C>T,
1759G>T, 2851C>T,
4180G>C
4181G>C
124G>A, 2850C>T, 4180G>C 124G>A, 2851C>T,
4181G>C

g.7955A>C
g.6778G>T, g.7870C>T,
g.9200G>C
g.5143G>A, g.7870C>T,
g.9200G>C

Decreased
function

rs5030865, rs16947,
rs1135840

1758G>A, 2850C>T,
4180G>C

1759G>A, 2851C>T,
4181G>C

g.6778G>A, g.7870C>T,
g.9200G>C

*15
*21

No function
No function

rs774671100
rs72549352, rs16947,
rs1135840

137_138insT
2579_2580insC, 2850C>T,
4180G>C

137_138insT
g.5156dup
2580_2581insC, 2851C>T, g.7599dup, g.7870C>T,
4181G>C
g.9200G>C

*31

No function

rs267608319, rs16947, 4042G>A, 2850C>T,
rs1135840
4180G>C

*40

No function

rs72549356,
rs28371706,
rs16947, rs1135840

*42

No function

rs72549346, rs16947,
rs1135840

*49

Decreased
function

rs1135822, rs1065852, 1611T>A, 100C>T, 4180G>C 1612T>A, 100C>T,
rs1135840
4181G>C

*56

No function

*59

Decreased
function
No function

rs72549347,
rs1135840
rs79292917, rs16947,
rs1135840
Variable

Hybrid
genes

4043G>A, 2851C>T,
4181G>C

g.9062G>A, g.7870C>T,
g.9200G>C

1863_1864insTTTCGCCCCT
TTCGCCCC,
1023C>T, 2850C>T,
4180G>C

1864_1865insTTTCGCCC
CTTTCGCCCC,
1022C>T, 2851C>T,
4181G>C

g.6875_6883TTTCGCCCC
[3], g.6041C>T,
g.7870C>T, g.9200G>C

3260_3261insGT, 2850C>T,
4180G>C

3261_3262insGT,
2851C>T, 4181G>C

g.8279_8280dup,
g.7870C>T, g.9200G>C
g.6631T>A, g.5119C>T,
g.9200G>C

3201C>T, 4180G>C

3202C>T, 4181G>C

g.8221C>T, g.9200G>C

2939G>A, 2850C>T,
4180G>C

2940G>A, 2851C>T,
4181G>C

g.7959G>A, g.7870C>T,
g.9200G>C

(table continues)
y

Citations for assignment of function can be found on the Pharmacogene Variation Consortium website (https://www.pharmvar.org, last
accessed October 28, 2020); HGVS nomenclature can be found on the National Center for Biotechnology Information website (https://www.
ncbi.nlm.nih.gov/snp and http://www.ncbi.nlm.nih.gov/clinvar, last accessed October 28, 2020).
z
Core variant(s) can be found on the Pharmacogene Variation Consortium website (https://www.pharmvar.org, last accessed October 28,
2020); the characteristic variant associated with altered function and corresponding HGVS nomenclature for each star allele are underlined.
x
Count from ATG start site.
{
The reference sequence initially used for deﬁning variants, M33388, differs from the current RefSeq NG_008376.4 at four positions, of
which three are insertion/deletions, and thus causes variant coordinates to shift among these reference sequences (PharmVar, https://www.
pharmvar.org/gene/cyp2d6, last accessed October 6, 2020). Positions on M33388 are referred to as legacy.
CPIC, Clinical Pharmacogenetics Implementation Consortium; HGVS, Human Genome Variation Society.

(p.Val338Met, rs59421388, legacy 3183G>A) and
c.406_408delinsATC (p.Val136Ile, rs61736512 þ rs1058164,
legacy 1659G>A and 1661G>C). This allele also includes the
two common variants, c.886C>T and c.1457G>C. Functionally, c.1012G>A (p.Val338Met) and c.406_408delinsATC (p.Val136Ile) together alter CYP2D6 enzyme
function.53 CYP2D6*29 has allele frequencies of 9% to 12% in
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those of African ancestry, 1.5% in Latinos, and <0.5% in
European and Asian (Central/South and East Asian) populations (PharmGKB, https://www.pharmgkb.org/gene/
pa128). Note that many platforms interrogate only c.
1012G>A due to the difﬁculty in testing for c.406_
408delinsATC. In addition, c.1012G>A is also present in
the CYP2D6 *70 and *109 haplotypes in combination with
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Table 3 (continued)
Reference
material
available

Multiethnic allele
frequency

HGVS genomic nomenclature:
GRCh38 (NC_000022.11)

HGVS cDNA nomenclature:
LRG_303 (NM_000106.6x)

HGVS protein nomenclature:
LRG_303 (NP_000097.3)

g.42127856T>G
g.42129033C>A,
g.42127941G>A,
g.42126611C>G
g.42130668C>T,
g.42127941G>A,
g.42126611C>G
g.42129033C>T,
g.42127941G>A,
g.42126611C>G
g.42130655dup
g.42128218dup,
g.42127941G>A,
g.42126611C>G
g.42126749C>T,
g.42127941G>A,
g.42126611C>G
g.42128934_
42128942AA
AGGGGCG[3],
g.42129770G>A,
g.42127941G>A,
g.42126611C>G
g.42127532_42127533dup,
g.42127941G>A,
g.42126611C>G
g.42129180A>T,
g.42130692G>A,
g.42126611C>G
g.42127590G>A,
g.42126611C>G
g.42127852C>T,
g.42127941G>A,
g.42126611C>G

c.971A>C
c.505G>T, c.886C>T,
c.1457G>C

p.His324Pro
p.Gly169Ter, p.Arg296Cys,
p.Ser486Thr

Yes
No

0%e0.6%
0%e0.1%

c.124G>A, c.886C>T,
c.1457G>C

p.Gly42Arg, p.Arg296Cys,
p.Ser486Thr

No

0%e1.7%

c.505G>A, c.886C>T,
c.1457G>C

p.Gly169Arg, p.Arg296Cys,
p.Ser486Thr

Yes

0%e0.3%

c.137dup
c.805dup, c.886C>T,
c.1457G>C

p.Leu47fs
p.Arg269fs, p.Arg296Cys,
p.Ser486Thr

Yes
Yes

0%e0.6%
0%e0.4%

c.1319G>A, c.886C>T,
c.1457G>C

p.Arg440His, p.Arg296Cys,
p.Ser486Thr

Yes

0%e0.8%

c.514_522TTTCGCCCC[3],
c.320C>T, c.886C>T,
c.1457G>C

p.172_174FRP[3], p.Thr107Ile,
p.Arg296Cys, p.Ser486Thr

Yes

0%e1.3%

c.1088_1089dup, c.886C>T,
c.1457G>C

p.Gln364fs, p.Arg296Cys,
p.Ser486Thr

No

0%e0.5%

c.358T>A, c.100C>T,
c.1457G>C

p.Phe120Ile, p.Pro34Ser,
p.Ser486Thr

No

0%e1.1%

c.1030C>T, c.1457G>C

p.Arg344Ter, p.Ser486Thr

Yes

0%e0.2%

c.975G>A, c.886C>T,
c.1457G>C

p.Pro325Z (splicing defect),
p.Arg296Cys, p.Ser486Thr

Yes

0%e0.7%

other sequence variants, but these alleles are rare, and their
function has not been well deﬁned.
CYP2D6*41
The decreased-function CYP2D6*41 allele is characterized
by a variant in intron 6 that causes a splice defect
(NM_000106.6: c.985þ39G>A, rs28371725, legacy
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2988G>A), resulting in decreased canonical CYP2D6
mRNA expression levels and enzyme function.54,55 This
haplotype also includes the common c.886C>T and
c.1457G>C variants. CYP2D6*41 has allele frequencies of
4% to 11.5% among individuals of African ancestry, 2% to
12% in Asian populations (East and Central/South Asian),
and approximately 9% in Europeans (PharmGKB, https://
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Table 4

Allele

Copy Number Detection for Selected Hybrid Alleles Composed of Portions of CYP2D6 and CYP2D7
Allele functional
statusy

*4.013 (*4N) No function
*13
No function
*36
No function
*68
No function
*83
Uncertain function

Reference Multiethnic
allele
material
available frequency

Hybrid type 50 UTRz Exon 1z Intron 2z Intron 5z Intron 6z Exon 9z

Yes
Yes
Yes
Yes

2D6-2D7
2D7-2D6
2D6-2D7
2D6-2D7
2D6-2D7

0%e0.4%
0%e1.2%
Not available
Not available

Yes
No
Yes
Yes
Yes

Yes
No
Yes
Yes
Yes

Yes
Yes/no
Yes
No{
Yes

Yes
Yes/no
Yes
No{
Yes

Yes
Yes/no
Yes
No{
Yes

No
Yesx
No
No
No

y

Allele functional status corresponds to CPIC clinical allele function assignments as listed in the CYP2D6 Allele Functionality Table available through
PharmGKB (https://www.pharmgkb.org/page/cyp2d6refmaterials, last accessed June 2, 2021); these function assignments are also displayed by the
Pharmacogene Variation Consortium.
z
Signal present on copy number analysis for this allele.
x
A hybrid with a switch to CYP2D6 past exon 9 has been described in tandem arrangements; these are technically also CYP2D7-2D6 hybrids and produce no
signal across any of the listed regions.
{
It cannot be ruled out that rare/undeﬁned hybrids switch in different regions affecting the copy number call in that region.
CPIC, Clinical Pharmacogenetics Implementation Consortium; HGVS, Human Genome Variation Society.

www.pharmgkb.org/gene/pa128). c.985þ39G>A is also
present in the CYP2D6 *32, *69, *91, *119, *123, and
*138 alleles.
CYP2D6xN (Gene Duplications/Multiplications)
The CYP2D6 locus is prone to structural variation, which can
result in two or more gene copies on a single haplotype as a
result of meiotic nonallelic homologous recombination
(https://www.pharmvar.org/gene/cyp2d6).16 Allelic variants
that are duplicated/multiplicated are annotated by PharmVar as
“N”, if the number of duplicated/multiplicated gene copies is
unknown. For duplicated allelic variants with known copy
number, it is commonly annotated as 2 (two copies), 3
(three copies), and so on. However, this nomenclature is not
standardized, and as a result, not every laboratory adheres to
this annotation for CYP2D6 duplication/multiplication alleles.
Thus, gene copy number may be reported by some clinical
laboratories as CYP2D6*1/*2/N, (*1/*2)dup, or (*1/*2)N,
for example. It is important to note that the functional effect of a
CYP2D6 duplication depends on which allele is duplicated.
The most commonly observed are *1N, *2N, *4N and
*41N20 (https://www.pharmvar.org/gene/cyp2d6). Some
laboratories can determine which allele is duplicated and
may use nomenclature that speciﬁes this information (eg,
*12/*4 vs *1/*42). The frequencies of duplicated alleles
in different populations are variable, and can be found at
https://www.pharmvar.org/gene/cyp2d6. Interrogation of
CYP2D6 gene duplications/multiplications is included in
Tier 1 due to the frequency of CYP2D6 gene-duplication
events in the general population, their effect on enzyme
function, and the feasibility of detection using common copy
number assays (eg, TaqMan, quantitative PCR, multiplex
ligation-dependent probe ampliﬁcation).

Tier 2 CYP2D6 Variant Alleles
The CYP2D6 variant alleles recommended for inclusion in
Tier 2 include CYP2D6 *7, *8, *12, *14, *15, *21, *31,
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*40, *42, *49, *56, and *59, and hybrid genes containing
portions of CYP2D6 and CYP2D7 (Table 3).
CYP2D6*7
The CYP2D6*7 allele is a no-function allele characterized
by a missense variant in exon 6 (NM_000106.6: c.971A>C,
p.His324Pro, rs5030867, legacy 2935A>C) that results in a
nonfunctional protein.56 This allele occurs at frequencies of
<0.05% in European and African ancestry populations and
between 0.01% and 0.6% in Asian populations (Central/
South and East Asian) (PharmGKB, https://www.pharmgkb.
org/gene/pa128).
CYP2D6*8
The CYP2D6*8 allele is a no-function allele characterized
by a nonsense variant in exon 3 (NM_000106.6: c.505G>T,
p.Gly169Ter, rs5030865, legacy 1758G>T) that results in a
nonfunctional protein.57 This allele also contains the common c.886C>T and c.1457G>C variants. It has been
identiﬁed in the European and American populations with
frequencies of 0.02% and 0.1%, respectively (PharmGKB,
https://www.pharmgkb.org/gene/pa128). Note that the
CYP2D6*8 c.505G>T variant is triallelic with
CYP2D6*14 (below).
CYP2D6*12
The no-function CYP2D6*12 allele is characterized by a
missense variant in exon 1 (NM_000106.6: c.124G>A,
p.Gly42Arg, rs5030862, legacy 124G>A), which results in a
nonfunctional protein.58,59 This allele also contains the common c.886C>T and c.1457G>C variants. It has been identiﬁed in the indigenous American populations with a frequency
of 1.7%, but less in Europeans, with a 0.02% frequency, and in
African ancestry populations with frequencies of 0.08% to
0.3% (PharmGKB, https://www.pharmgkb.org/gene/pa128).
Because RMs are not available for CYP2D6*12, it is
currently classiﬁed as a Tier 2 allele. This categorization is
subject to change should RMs become available.
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Table 5

Number/Percentage of Laboratories that Report Testing for Speciﬁc CYP2D6 Alleles from Proﬁciency Testing Data

Allele
*2
*2A
*3
*4
*5 (Deletion)
*6
*7
*8
*9
*10
*11
*12
*14
*15
*17
*21
*29
*31
*35
*40
*41
*42
*49
*56
*59
Duplication
Hybrid alleles

Tier
1

*36 (alone or as part of *36þ*10)

1
1
1
1
2
2
1
1
No tier
2
2
2
1
2
1
2
No tier
2
1
2
2
2
2
1
2

CAP PGx, n (%)

MG2, n (%)

135 (96.4)
29 (20.7)
131 (93.6)
138 (98.6)
122 (87.1)
134 (95.7)
124 (88.6)
122 (87.1)
132 (94.3)
134 (95.7)
67 (47.9)
99 (70.7)
88 (62.9)
60 (42.9)
130 (92.9)
N.D.
118 (84.3)
N.D.
71 (50.7)
N.D.
133 (95.0)
N.D.
N.D.
N.D.
N.D.
123 (87.9)
24 (17.1)

37 (74.0)
N.D.
50 (100)
50 (100)
49 (98.0)
48 (96.0)
26 (52.0)
26 (52.0)
34 (68.0)
38 (76.0)
N.D.
N.D.
N.D.
N.D.
28 (56.0)
N.D.
N.D.
N.D.
16 (32.0)
N.D.
40 (80.0)
N.D.
N.D.
N.D.
N.D.
47 (94.0)
N.D.

Speciﬁc CYP2D6 alleles that are queried in the College of American Pathologists (CAP) PGx and/or the German Reference Institute for Bioanalytics Molecular
Genetics Group (MG)-2 proﬁciency testing surveys are listed, along with the tier assigned in the present article. The numbers and percentages of laboratories
that reported that they test for the allele are provided. All alleles included in the CAP and/or MG2 surveys were listed, although *11 and *35 were not assigned
to tier 1 or 2. Additionally, several alleles assigned to tier 2 are included in this table despite not being part of the CAP or MG2 survey (eg, *21, *31, *40, *42,
*49, *56, *59).
N.D., no data on that allele were available from the survey.

CYP2D6*14
The decreased-function CYP2D6*14 allele is characterized by
a missense variant in exon 360 (NM_000106.6:c.505G>A,
p.Gly169Arg, rs5030865, legacy 1758G>A), causing
decreased enzyme function.51 A G>T (c.505G>T) change in
the same triallelic position (rs5030865) is observed in the
CYP2D6*8 allele. The common c.886C>T and c.1457G>C
variants are both present in the CYP2D6*14 haplotype. This
allele has been detected primarily in the East Asian population,
with a reported frequency of 0.3% (PharmGKB, https://www.
pharmgkb.org/gene/pa128). The variant c.505G>A is also
present on the CYP2D6*114 no-function allele in combination with the c.100C>T and the common c.886C>T and c.
1457G>C variants. CYP2D6*14A was changed to
CYP2D6*114.001 because the function of this allele (no
function) is different from the more common decreasedfunction *14B (*14.001) allele. CYP2D6*114 has been
detected primarily in the East Asian population, with a reported
frequency of 0.08% (PharmGKB, https://www.pharmgkb.org/
gene/pa128).
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CYP2D6*15
CYP2D6*15 is a no-function allele characterized by a
T insertion in exon 1 causing a frameshift
(NM_000106.6:c.137dup, p.Leu47fs, rs774671100, legacy
137_138insT) and resulting in a premature stop codon,
truncation of the CYP2D6 protein, and loss of enzyme
function.61 This allele has frequencies of approximately
0.6% in African ancestry populations and <0.05% in European and Asian populations (Central/South and East
Asian) (PharmGKB, https://www.pharmgkb.org/gene/
pa128).
CYP2D6*21
The no-function CYP2D6*21 allele is characterized by an
insertion of a C in exon 5, causing a frameshift
(NM_000106.6:c.805dup, p.Arg269fs, rs72549352, legacy
2579_2580insC) that results in a premature stop codon,
truncation of the CYP2D6 protein, and nonfunctional
enzyme.62,63 CYP2D6*21 also contains c.886C>T and
c.1457G>C. This allele has been identiﬁed in the East Asian
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population with an allele frequency of approximately 0.4%
(PharmGKB, https://www.pharmgkb.org/gene/pa128).
CYP2D6*31
The no-function CYP2D6*31 allele is characterized by a
missense variant in exon 9 (NM_000106.6:c.1319G>A,
p.Arg440His, rs267608319, legacy 4042G>A), resulting in
nonfunctional protein.64,65 This haplotype also contains
c.886C>T and c.1457G>C. The allele frequency of
CYP2D6*31 among most populations is currently unclear;
however, it has been found at a frequency of <1% in European and Latino populations (PharmGKB, https://www.
pharmgkb.org/gene/pa128). GnomAD reports this variant,
c.1319G>A, at a frequency of <0.1% in African,
European (Finnish and non-Finnish), Latino, and Asian
populations
(gnomAD
browser,
https://gnomad.
broadinstitute.org/variant/22-42522751-c-t?datasetZgnomad_
r2_1, last accessed October 29, 2020).
CYP2D6*40
The no-function CYP2D6*40 allele is characterized by an inframe insertion of 18 bp consisting of a duplication of a 9-bp
sequence (TTTCGCCCC  2) in exon 4 (NM_000106.6:
c.514_522TTTCGCCCC[3],
p.172_174FRP[3],
rs7254
9356, legacy 1863_1864insTTTCGCCCCTTTCGCCCC),
rendering the protein nonfunctional.66 This allele also contains
the variant in CYP2D6*17, c.320C>T, and the common
c.886C>T and c.1457G>C variants. The frequency of
CYP2D6*40 ranges from 0.5% to 1.3% in those of African
ancestry but is <0.1% in the European population (PharmGKB,
https://www.pharmgkb.org/gene/pa128). Importantly, if the inframe 18-bp insertion is not speciﬁcally tested, the c.320C>T
allele receives a CYP2D6*17 default assignment, which is
notable given that CYP2D6*40 is a no-function allele and
CYP2D6*17 is a decreased-function allele. In addition, a similar
9-bp (TTTCGCCCC) insertion variant is present in the
CYP2D6 *30 and *58 alleles. As such, the CYP2D6*40 allele
was reassigned to Tier 2 despite having RMs, a >1% minor
allele frequency, and well-deﬁned function due to the difﬁculties
of detecting and discriminating the 9- and 18-bp insertions.
CYP2D6*42
The no-function CYP2D6*42 allele is characterized by an
insertion
of
two
nucleotides
in
exon
7
(NM_000106.6:c.1088_1089dup, p.Gln364fs, rs72549346,
legacy 3260_3261insGT) that cause a frameshift and premature stop codon, resulting in a truncated and nonfunctional
CYP2D6 protein.67 CYP2D6*42 also contains the c.886C>T
and the c.1457G>C variants. This allele has been identiﬁed
in those of African ancestry and in the Central/South Asian
population with an allele frequency of <0.5% (PharmGKB,
https://www.pharmgkb.org/gene/pa128).
CYP2D6*49
The decreased-function CYP2D6*49 allele is characterized
by
a
missense
variant
in
exon
368
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(NM_000106.6:c.358T>A, p.Phe120Ile, rs1135822, legacy 1611T>A). The haplotype also includes the c.100C>T
and the c.1457G>C variants. The c.358T>A and
c.100C>T together contribute to decreased enzyme function.51,52 The CYP2D6*49 allele has been found in the East
Asian population with a frequency of about 1%
(PharmGKB, https://www.pharmgkb.org/gene/pa128). The
deﬁning variant of CYP2D6*49, c.358T>A, is also
present in the CYP2D6*53 allele. The variant c.358T>A
is also found in combination with another variant on the
CYP2D6*53 allele. Because RMs are not available for
CYP2D6*49, it is currently classiﬁed as a Tier 2 allele.
This categorization is subject to change should RMs
become available.
CYP2D6*56
The no-function CYP2D6*56 allele is characterized by a
nonsense variant in exon 7 (NM_000106.6:c.1030C>T,
p.Arg344Ter, rs72549347, legacy 3201C>T) that generates
a stop codon resulting in nonfunctional truncated protein.69,70 This haplotype also contains the common
c.1457G>C variant. The CYP2D6*56 allele has been
identiﬁed in those of African ancestry or European populations with a frequency of <0.2% (PharmGKB, https://
www.pharmgkb.org/gene/pa128). Some suballeles of
CYP2D6*56 contain the c.100C>T variant, such as *56.
002 and *56.003. If the CYP2D6*56 deﬁning variant (c.
1030C>T) is not tested, these suballeles are defaulted to
CYP2D6*10.
CYP2D6*59
The decreased-function CYP2D6*59 allele is characterized
by a splice variant at the end of exon 6
(NM_000106.6:c.975G>A, p.Pro325Z, rs79292917, legacy 2939G>A) that results in decreased canonical mRNA
expression levels, protein, and enzyme activity.71 This
haplotype also contains the common c.886C>T and
c.1457G>C variants. This allele has been found in the
European population with a frequency of 0.7%
(PharmGKB, https://www.pharmgkb.org/gene/pa128).
Hybrid Alleles
Due to the high-sequence homology between CYP2D6 and
CYP2D7, hybrid alleles with gene conversions are also
present in the general population. The hybrid alleles can
contain the 50 region of CYP2D6 followed by conversion to
CYP2D7 sequence, or the 50 region of CYP2D7 followed by
conversion to CYP2D6 sequence, which have been
consolidated under the CYP2D6*13 designation by
PharmVar.72 These hybrid alleles can be independent or in
tandem with one or more full copies of the CYP2D6
gene17,73 (PharmVar, https://www.pharmvar.org/gene/
cyp2d6). Hybrid alleles have a frequency of approximately
1% in East Asians and are less common in other
populations (PharmGKB, https://www.pharmgkb.org/gene/
pa128).
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Because hybrid alleles are technically more challenging to
characterize, the Working Group included these alleles in
Tier 2. While most CYP2D6 hybrid alleles are generally
considered to be nonfunctional, they can complicate CYP2D6
copy number analysis, particularly if the test queries CYP2D6
gene copy number at only one position.27,73,74 For example,
if a laboratory’s copy number assay is designed to query exon
1 of CYP2D6 and a CYP2D6-CYP2D7 hybrid gene is present, the laboratory may mistake the hybrid gene for a full
copy of the CYP2D6 gene (Table 4). Using only one location
within CYP2D6 for copy number can satisfy the Tier 1
recommendation to identify the CYP2D6*5 deletion or gene
duplication; however, it is recommended at least two, if not
multiple locations, be used for detecting hybrid alleles.
Ideally, targeting the 50 untranslated region or exons 1 and 9,
thus covering both ends of the gene, is advised to differentiate full copies of CYP2D6 from hybrid alleles. While the
Working Group believes that it is important to detect hybrid
alleles for Tier 2 recommendations, complete characterization
of the hybrid alleles is less important as most are
nonfunctional.

Quality Assessments
Proﬁciency testing programs are commercially available
for some of the CYP2D6 alleles. Recent data from CAP
proﬁciency testing and the German Reference Institute
for Bioanalytics Molecular Genetics Group 2 were
assessed to determine which CYP2D6 alleles are
currently tested by participating laboratories, and to
assess the potential challenges in the implementation of
these recommendations.
The numbers and percentages of laboratories that reported
testing for each CYP2D6 allele in the CAP 2019 PGx-B and
Molecular Genetics Group 2 (MG21/20; April 2020) surveys are presented in Table 5. While 247 laboratories
participated in the CAP 2019 PGX-B survey, data are based
on the 140 (56.7%) that indicated which alleles are included
in their clinical CYP2D6 test. The European Molecular
Genetics Quality Network (https://www.emqn.org, last
accessed October 6, 2020) has a pilot panel for PGx
(Pharmaco-20), covering 45 variants in various
pharmacogenes, including CYP2D6. No information is
provided regarding which CYP2D6 alleles were
characterized, nor is an outcome report publicly available.
Several supplemental questions were asked to facilitate a
better understanding of the processes that laboratories use
for CYP2D6 testing. Of the 140 laboratories that provided
information on the CYP2D6 alleles included in their testing,
138 responded to the supplemental question regarding
whether they perform gene-duplication/CNV testing. Of
those 138 laboratories, 125 (90.6%) indicated that they
perform CNV testing, while 13 laboratories responded that
they do not. Twenty-nine did not respond to the question
about how many positions within the CYP2D6 gene are
tested in their CNV assay. Of the 111 laboratories that
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responded, 63 (56.8%) indicated that they query a single
position within the gene, 41 (36.9%) evaluate multiple positions, and 7 indicated “other.” When asked whether the
laboratory was able to differentiate between a whole gene
duplication/multiplication versus the presence of a hybrid
allele, 124 laboratories responded. Of the 124, 72 laboratories (58.1%) indicated that they are not able to, while 37
(29.8%) indicated that they can, and 15 (12.1%) responded
that they were unsure.

Discussion
In the present article, the AMP PGx Working Group describes
recommendations on alleles to be included in clinical CYP2D6
genotyping assays. As with other published AMP PGx
guidelines, alleles were selected and stratiﬁed as Tier 1 or 2
recommendations, based on priority-based criteria for testing
as deﬁned by the Working Group. The Tier 1 variant alleles are
recommended to be included as a minimum panel in all clinical
CYP2D6 genotyping tests and were selected for inclusion
based on their effects on the CYP2D6 gene, CYP2D6 protein
expression or enzyme function, frequency in a subset of the
population, and availability of RMs. In addition, the Working
Group considered the feasibility of detecting Tier 1 alleles
using current molecular methods that are widely available to
clinical laboratories, acknowledging that it is not practical to
expect laboratories to detect complex, rare variants that are not
readily detectable by routine methods (eg, gene conversions,
structural variants, phasing of variants, or determination of the
type and number of gene-duplication events).
The goals of these recommendations are to promote
standardization among clinical laboratories and to ensure
that clinical PGx tests include, at a minimum, those variant
alleles that are present in approximately 1% or more of a
human subpopulation and have a well-documented effect on
enzyme function, unless not technically feasible. Failure to
test for any of the Tier 1 alleles could result in inaccurate
prediction of phenotype function in a signiﬁcant proportion
of the tested population. The Tier 2 alleles are included for
clinical laboratories that desire to provide more comprehensive testing for rarer alleles with a deﬁned effect on
function and/or those without RMs readily available for
assay validation. Of note, the Tier 1 recommendations
detect the majority of known nonewild-type CYP2D6
variation (ie, non-*1 alleles) in major ethnic groups (78%
of African Americans, approximately 84% of European
Caucasians, and approximately 85% of East Asians), based
on published data on allele frequency (PharmGKB, https://
www.pharmgkb.org/gene/pa128). When both Tier 1 and
Tier 2 recommended alleles are tested, the capacity to
detect known nonewild-type CYP2D6 variation is higher
(80% African Americans, approximately 85% European
Caucasians, approximately 87% East Asians). The
Working Group acknowledges that functionally important,
rare alleles may occur in isolated populations, and that
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clinical laboratories may also choose to include additional
alleles that are representative of their tested population.
CYP2D6 variants or alleles without sufﬁcient evidence of
functional effect are not recommended for routine clinical
testing. All clinical laboratories should follow best
practices for assay validation and adhere to the applicable
regulatory requirements of their location.
Genetic testing of pharmacogenes, such as CYP genes,
relies on inferring star alleles or haplotypes, based on the
results of genotyped variants. For a highly polymorphic
gene such as CYP2D6, interrogation of a single sequence
variant is often not sufﬁcient to call an allele/haplotype. As
with all PGx genotyping, it is recognized that a lack of
detection of rare sequence variants that are not included in
the assay will result in a default wild-type call or normal
allele (eg, CYP2D6*1) assignment. Similarly, rare variants
that occur on a speciﬁc haplotype and that are not tested will
result in a default call of the more common haplotype that
includes a subset of the variants, which may, in turn, result
in an incorrect phenotype prediction. For example, the Tier
1 alleles CYP2D6 *17, *29, and *41 should be identiﬁed not
only by the variant that characterizes the allele, but also by
the presence of the c.886C>T variant. On the other hand,
the two common variants, c.886C>T and c.1457G>C, are
present in many Tier 1 (*2, *17, *29, and *41) and Tier 2
(*8, *12, *14, *21, *31, *40, and *59) alleles, as well as
many other rare alleles. Thus, lack of detection of the core
variants for these alleles will result in a default CYP2D6*2
allele assignment (normal function). This is a caveat of all
genetic testing based on haplotype calling, and emphasizes
the need for inclusion of the most common variant alleles in
clinical genotyping assays. It is recommended that laboratories include a caveat statement in their reports that additional or rare variants may be present that could affect a
patient’s predicted phenotype.
CYP2D6 genotyping is technically challenging due to the
presence of CNVs and more complex gene-conversion
events associated with some variant alleles in the general
population. Through homologous recombination, gene
deletion and duplication events have occurred through
evolution, with reports of some individuals having as many
as 13 tandem copies of a functional CYP2D6 gene.75
Therefore, the identiﬁcation of gene deletion (CYP2D6*5)
and gene duplications/multiplications (CYP2D6N ) is
considered an essential aspect of clinical CYP2D6 testing
and is achievable using commercially available copy number assays. However, many methods/platforms cannot
determine the exact number of gene copies on an allele or
which of the two chromosomal alleles harbors the geneduplication event. Therefore, in some cases it may not be
possible to determine whether a functional or decreased-/nofunction allele is duplicated (eg, to discriminate between
CYP2D6 *22/*4 and *2/*42, or *23/*4 and *22/
*42). This is a caveat of many clinically available tests
that is recognized by the Working Group, and the determination of the number of gene copies and function is not
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considered as Tier 1 at this time. Similarly, the detection of
hybrid alleles is not considered Tier 1, as their accurate
detection is technically challenging. The Working Group
includes information on the detection of hybrid alleles in
Tier 2 for clinical laboratories that desire to incorporate a
more comprehensive genotyping analysis of these complex
alleles. Such analyses can be useful for determining the
assessment of CYP2D6 gene function in individual patients
and thereby improve the accuracy of phenotype predictions.

Clinical Applications
There are six published CPIC guidelines that involve
CYP2D6-metabolized medications: tamoxifen,4 ondansetron
and tropisetron,5 tricyclic antidepressants,6 selective serotonin
reuptake inhibitors,7 select opioids including codeine,8 and
atomoxetine.9 In addition, FDA-approved labels of over 20
medications include dosing recommendations based on
CYP2D6 phenotype, and the labels of over 70 additional
medications include informative statements on the impact of
CYP2D6 phenotype on drug exposure (CPIC, https://cpicpgx.
org/genes-drugs, last accessed November 13, 2020). The
importance of CYP2D6 phenotype on drug therapy in
patients with psychiatric disease was underlined in a recent
review of PGx testing in psychiatry,76 as well as in a recommendation from the International Society of Psychiatric Genetics: genetics information on CYP2D6 along with CYP2C19
would likely be most beneﬁcial in patients who have experienced an inadequate response or an adverse reaction to a previous trial of an antidepressant or antipsychotic (International
Society of Psychiatric Genetics, https://ispg.net/genetictesting-statement, last accessed October 29, 2020).

CYP2D6 Alleles Not Included in Tier 1 or 2
Recommendations
According to the data on frequency from CPIC, the
CYP2D6*11 allele (NM_000106.6:c.181-1G>C, rs20137
7835, legacy 883G>C) has a MAF of up to 0.1% in the European population. However, according to gnomAD, the
variant that characterizes this allele is most common in the nonFinnish European population, with an MAF of 0.025%, which
falls below the deﬁned cutoff of 0.1% MAF for inclusion in
Tier 2. Although the gnomAD data report the MAF of a single
variant, it is recognized that no haplotype can be present in the
population more frequently than any individual variant contained within the haplotype. Therefore, despite the data on
frequency from CPIC, this allele is not recommended in either
tier at this time due to its overall low frequency based on data
on population from gnomAD.
CYP2D6*69 is a no-function allele that is difﬁcult to
discriminate from other alleles and is therefore not included in
the Tier 1 or 2 recommendations. The variants that are present
in CYP2D6*69 (c.100C>T, c.886C>T, c.985þ39G>A, and
c.1457G>C) are also present in many other commonly
detected CYP2D6 alleles, including *2, *10, and *41. When
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these four variants are heterozygous, it is difﬁcult to discriminate the rare CYP2D6 *1/*69 diplotype from the more
commonly observed *10/*41 diplotype unless additional
testing is undertaken, such as testing for c.352þ7A>G,
rs267608289, which appears to be unique to *69, or establishing that c.100C>T, c.886C>T, c.985þ39G>A, and
c.1457G>C are on the same haplotype (eg, by using methods
for establishing linkage, eg, allele-speciﬁc ampliﬁcation
combined with real-time PCR ampliﬁcation, or parent
testing).77 Thus, it is common practice to default to
CYP2D6*10/*41, based on observed allele frequencies that
may underestimate the frequency of *69 (PharmGKB, https://
www.pharmgkb.org/gene/pa128). Given that both CYP2D6
*1/*69 and*10/*41 are associated with intermediate
metabolism, this distinction does not affect phenotype
assignment. A CYP2D6*69 allele may be identiﬁed by
atypical or unexpected variants present in a patient, that
cannot otherwise be reconciled. A case in point is a patient
in whom this allele was ﬁrst discovered and ultimately
genotyped as CYP2D6*4/*69.77 Sequence analysis would
also facilitate the identiﬁcation of CYP2D6*69.
A CYP2D6 enhancer variant (NM_152613.3:c.632604G>A, rs5758550), located 116 Kbp downstream of the
CYP2D6 gene, was suggested to affect CYP2D6 activity by
modulating expression levels, and through this mechanism
account for unexplained variability in CYP2D6 activity
in vivo.78,79 The investigators proposed that this enhancer
variant, in combination with c.886C>T, which is present on
CYP2D6*2 and many other alleles, should be included in PGx
test panels as it may be predictive of functional activity. The
ﬁndings from one subsequent study, however, contradicted
these ﬁndings.80 Speciﬁcally, in the latter publication, the investigators did not ﬁnd an effect of rs5758550 on the formation
of endoxifen in breast cancer patients taking tamoxifen.
Additional studies are needed for corroborating the initial hypothesis that the enhancer variant has a clinically relevant
impact on CYP2D6 activity, which would warrant its inclusion
in clinical PGx genotyping panels. Furthermore, rs5758550
not only is present in CYP2D6*2, where it was originally
discovered, but also was recently shown to occur in many other
haplotypes including decreased- and no-function alleles.81
Therefore, due to limited evidence, the Working Group does
not recommend testing for the rs5758550 variant.

discussed in this document, the Working Group does not
recommend or endorse any particular molecular testing platforms for CYP2D6 genotyping.

Conclusion
This document provides recommendations on PGx alleles to
include in clinical tests for CYP2D6 genotyping. These
recommendations are intended to facilitate the design and
implementation of genetic testing by clinical laboratories. In
addition, these recommendations are intended to promote
test standardization and genotype concordance between
laboratories.

Disclaimer
The AMP Clinical Practice Guidelines and Reports are
developed to be of assistance to laboratory and other health
care professionals by providing guidance and recommendations for particular areas of practice. The Guideline or
Report should not be considered inclusive of all proper
approaches or methods, or exclusive of others. The Guideline or Report cannot guarantee any speciﬁc outcome, nor
does it establish a standard of care. The Guideline or Report
is not intended to dictate the treatment of a particular patient. Treatment decisions must be made based on the independent judgment of health care providers and each
patient’s individual circumstances. The AMP makes no
warranty, express or implied, regarding the Guideline or
Report and speciﬁcally excludes any warranties of
merchantability and ﬁtness for a particular use or purpose.
The AMP shall not be liable for direct, indirect, special,
incidental, or consequential damages related to the use of
the information contained herein.
The ﬁndings and conclusions in this report are those of
the authors and do not necessarily represent the ofﬁcial
position of the Centers for Disease Control and Prevention/
the Agency for Toxic Substances and Disease Registry. The
use of trade names and commercial sources is for identiﬁcation only and does not imply endorsement by the Centers
for Disease Control and Prevention, the Public Health Service, or the US Department of Health and Human Services.
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